Skip to main content

Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal

Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built a portfolio of eight radiopharmaceuticals.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.